Clinical implications of transforming growth factor-beta–induced gene-h3 protein expression in lung cancer
Authors He C, Sun D, Bai X, Li Y, Xu H, Xu S
Received 8 November 2015
Accepted for publication 17 February 2016
Published 11 August 2016 Volume 2016:9 Pages 4983—4987
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Federico Perche
Peer reviewer comments 3
Editor who approved publication: Professor Min Li
Changjun He,1,* Dawei Sun,1,* Xue Bai,1 Yingbin Li,2 Hai Xu,1 Shidong Xu1
1Department of Thoracic Surgery, Cancer Hospital of the Harbin Medical University, 2Department of Pain Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
*These authors contributed equally to this work
Aim: The clinical implications of transforming growth factor-beta–induced gene-h3 (beta-IGH3) protein expression in lung cancer remain unclear. This study investigated beta-IGH3 protein expression levels and biological function, as well as lung cancer prognosis.
Methods: Beta-IGH3 protein expression levels were measured in 236 lung cancers and were matched with adjacent noncancerous tissues by immunohistochemical staining. Subsequently, the relationship between beta-IGH3 protein expression, clinical–pathological parameters, and lung cancer prognosis was evaluated.
Results: Beta-IGH3 protein expression was significantly higher in lung cancer tissues compared with adjacent noncancerous tissues (61.86% vs 22.88%; P=0.01). Of the 236 enrolled cases, 146 (61.86%) showed high beta-IGH3 levels. Tumor size, clinical stage, and lymph node metastasis were significantly related to beta-IGH3 protein expression in univariate analysis (P=0.001, 0.044, and 0.029, respectively), whereas age, sex, and histological type were not (P=0.038, 0.756, and 0.889, respectively). Finally, a Cox regression model also identified beta-IGH3 as an independent prognostic factor (P=0.01).
Conclusion: Beta-IGH3 is highly expressed in lung cancers and may be a potential target for lung cancer treatments.
Keywords: lung cancer, beta-IGH3 protein, lymph node, metastasis, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]